Yd Biopharma Limited (YDES)

$12.50 +4.50 (56.25%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin -7,451.52%
Debt to Equity Ratio 0.92
Volume 916,200
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.

Industry: Biotechnology
Sector: Healthcare
Address:
No. 3, Xingnan St., 12F. Nangang Dist., Taipei, Taiwan
CEOBuysDisclosures
CEOBuysDisclosures Sep. 10 at 10:10 PM
$YDES CEO purchased 3,100 shares at $3.93 for a total of $12,183. Shen Ethan PhD now owns 54,366,489 shares. https://ceo-buys.com
0 · Reply
hanna938
hanna938 Sep. 9 at 3:07 PM
$YDES
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Sep. 8 at 10:05 PM
$YDES CEO purchased 18,378 shares at $3.67 for a total of $67,447. Shen Ethan PhD now owns 54,363,389 shares. https://ceo-buys.com
0 · Reply
focafoca99
focafoca99 Aug. 31 at 10:15 PM
$YDES released six-month 2026 results, turning to profitability with $6.7M net income and 315% revenue jump to $847K.
0 · Reply
madkomodo
madkomodo Aug. 31 at 3:43 PM
$YDES why so long?
0 · Reply
topstockalerts
topstockalerts Aug. 30 at 10:03 PM
Top Gainers PT2. $DUO $NCPL $ORIO $TJGC $YDES
0 · Reply
topstockalerts
topstockalerts Aug. 29 at 5:49 PM
Top Gainers PT2 $DUO $NCPL $ORIO $TJGC $YDES
0 · Reply
topstockalerts
topstockalerts Aug. 29 at 1:27 PM
Top Gainers PT2 $DUO $NCPL $ORIO $TJGC $YDES
0 · Reply
topstockalerts
topstockalerts Aug. 28 at 9:42 PM
Top Gainers PT2 $DUO $NCPL $ORIO $YDES $CLGN
0 · Reply
NNTrader
NNTrader Jul. 27 at 8:05 PM
$YDES something cooking
0 · Reply
Latest News on YDES
YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

Aug 31, 2026, 6:00 PM EDT - 17 days ago

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

Aug 25, 2026, 8:00 AM EDT - 23 days ago

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

Jul 28, 2026, 8:00 AM EDT - 7 weeks ago

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

Jul 23, 2026, 8:00 AM EDT - 1 month ago

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

Jul 2, 2026, 8:00 AM EDT - 2 months ago

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

YD Bio Limited Reports Full Year 2025 Financial Results

Apr 30, 2026, 6:00 PM EDT - 4 months ago

YD Bio Limited Reports Full Year 2025 Financial Results

YD Bio Ltd trading halted, volatility trading pause

2026-04-07T20:01:22.000Z - 5 months ago

YD Bio Ltd trading halted, volatility trading pause

YD Bio Ltd trading resumes

2026-04-07T20:00:16.000Z - 5 months ago

YD Bio Ltd trading resumes

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

Mar 31, 2026, 8:00 AM EDT - 5 months ago

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

YD Bio Ltd trading resumes

2026-03-23T13:51:11.000Z - 5 months ago

YD Bio Ltd trading resumes

YD Bio Ltd trading halted, volatility trading pause

2026-03-23T13:47:18.000Z - 5 months ago

YD Bio Ltd trading halted, volatility trading pause

YD Bio details roadmap for integrated oncology ecosystem

2026-03-17T12:36:55.000Z - 6 months ago

YD Bio details roadmap for integrated oncology ecosystem

YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem

Mar 17, 2026, 8:00 AM EDT - 6 months ago

YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem

YD Bio announces partnership with YC Biotech

2026-02-25T13:21:02.000Z - 6 months ago

YD Bio announces partnership with YC Biotech

YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform

Feb 25, 2026, 8:00 AM EST - 6 months ago

YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform

YD Bio enters into binding LOI to acquire shares, assets of SSMC

2026-01-29T13:46:09.000Z - 7 months ago

YD Bio enters into binding LOI to acquire shares, assets of SSMC

YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy

Jan 29, 2026, 8:30 AM EST - 7 months ago

YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy

YD Bio enters MOU to merge with EG BioMed

2026-01-06T14:11:59.000Z - 8 months ago

YD Bio enters MOU to merge with EG BioMed

YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development

Jan 6, 2026, 9:00 AM EST - 8 months ago

YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development

YD Bio unveils 2026 clinical, commercial roadmap

2026-01-05T14:16:13.000Z - 8 months ago

YD Bio unveils 2026 clinical, commercial roadmap

YD Bio unveils 2026 clinical, commercial roadmap

2026-01-05T14:16:05.000Z - 8 months ago

YD Bio unveils 2026 clinical, commercial roadmap

YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap

Jan 5, 2026, 9:00 AM EST - 8 months ago

YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap

YD Bio announces newly planned California facilities, operations center

2025-12-16T14:05:18.000Z - 9 months ago

YD Bio announces newly planned California facilities, operations center

YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center

Dec 16, 2025, 9:00 AM EST - 9 months ago

YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center

YD Bio showcases diagnostic, precision medicine portfolios

2025-12-09T14:11:09.000Z - 9 months ago

YD Bio showcases diagnostic, precision medicine portfolios

YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN

Dec 9, 2025, 9:00 AM EST - 9 months ago

YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN

YD Bio provides update on OkaiDx testing portfolio

2025-12-03T09:05:30.000Z - 9 months ago

YD Bio provides update on OkaiDx testing portfolio

YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection

Dec 2, 2025, 9:00 AM EST - 9 months ago

YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection

YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics

Nov 24, 2025, 9:00 AM EST - 9 months ago

YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics

YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring

Nov 5, 2025, 8:30 AM EST - 10 months ago

YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring

YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES

Oct 20, 2025, 10:20 AM EDT - 11 months ago

YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES

YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities

Oct 10, 2025, 8:37 AM EDT - 11 months ago

YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities

YD Bio Limited Reports Unaudited Half Year 2025 Financial Results

Sep 30, 2025, 5:25 PM EDT - 11 months ago

YD Bio Limited Reports Unaudited Half Year 2025 Financial Results

YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market

Aug 29, 2025, 7:30 AM EDT - 1 year ago

YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market

CEOBuysDisclosures
CEOBuysDisclosures Sep. 10 at 10:10 PM
$YDES CEO purchased 3,100 shares at $3.93 for a total of $12,183. Shen Ethan PhD now owns 54,366,489 shares. https://ceo-buys.com
0 · Reply
hanna938
hanna938 Sep. 9 at 3:07 PM
$YDES
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Sep. 8 at 10:05 PM
$YDES CEO purchased 18,378 shares at $3.67 for a total of $67,447. Shen Ethan PhD now owns 54,363,389 shares. https://ceo-buys.com
0 · Reply
focafoca99
focafoca99 Aug. 31 at 10:15 PM
$YDES released six-month 2026 results, turning to profitability with $6.7M net income and 315% revenue jump to $847K.
0 · Reply
madkomodo
madkomodo Aug. 31 at 3:43 PM
$YDES why so long?
0 · Reply
topstockalerts
topstockalerts Aug. 30 at 10:03 PM
Top Gainers PT2. $DUO $NCPL $ORIO $TJGC $YDES
0 · Reply
topstockalerts
topstockalerts Aug. 29 at 5:49 PM
Top Gainers PT2 $DUO $NCPL $ORIO $TJGC $YDES
0 · Reply
topstockalerts
topstockalerts Aug. 29 at 1:27 PM
Top Gainers PT2 $DUO $NCPL $ORIO $TJGC $YDES
0 · Reply
topstockalerts
topstockalerts Aug. 28 at 9:42 PM
Top Gainers PT2 $DUO $NCPL $ORIO $YDES $CLGN
0 · Reply
NNTrader
NNTrader Jul. 27 at 8:05 PM
$YDES something cooking
0 · Reply
barleycorn
barleycorn Jul. 9 at 4:54 PM
$YDES why is no one here. it only takes a few shares to move this.
0 · Reply
rapidtrades
rapidtrades Jul. 8 at 3:00 PM
$YDES $3
0 · Reply
AshCash93
AshCash93 Jul. 8 at 6:11 AM
$CAST $ELTX $NTCL $OPTU $YDES
1 · Reply
BillionerOfKing
BillionerOfKing Jul. 7 at 11:58 PM
$YDES Current Stock Price: $1.98
0 · Reply
FibonacciTrader_
FibonacciTrader_ Jul. 7 at 9:24 PM
I mportant awakening Currently, five stocks are trading at a discount today and are poised to hit all-time highs within less than three months: $ELTX -37.4% $CAST -27.7% $NTCL -26.5% $OPTU -25.5% $YDES -17.8% Bookmark this post for later! Next alert is coming soon. If you’re not following with notifications on, you’re likely seeing the move after it already happened.
0 · Reply
rapidtrades
rapidtrades Jul. 7 at 4:54 PM
$YDES bouncing back after lunch folks
0 · Reply
TheTaurusBull38
TheTaurusBull38 Jul. 7 at 4:38 PM
$YDES this stock licks ballz
0 · Reply
rapidtrades
rapidtrades Jul. 7 at 4:38 PM
$YDES rejoined
0 · Reply
F14TOMCATIIAF
F14TOMCATIIAF Jul. 7 at 9:49 AM
$YDES 3 or more
0 · Reply